Besides, LRP1B mutation in HCC was significantly associated with a higher TMB and higher expression of immune checkpoint gene HHLA2, providing new evidence to search for more straightforward, complementary, or alternative approaches to TMB as therapeutic markers for immune checkpoint inhibition. Here, LRP1B is linked to hepatocellular carcinoma.